Progranulin antibodies in autoimmune diseases

Journal of Autoimmunity

Volumn 42, Issue , 2013, Pages 29-38

  Thurner, Lorenz ^a   Preuss, Klaus Dieter ^a   Fadle, Natalie ^a   Regitz, Evi ^a   Klemm, Philipp ^a   Zaks, Marina ^a   Kemele, Maria ^a   Hasenfus, Andrea ^a   Csernok, Elena ^b   Gross, Wolfgang L ^c   Pasquali, Jean Louis ^c   Martin, Thierry ^c   Bohle, Rainer Maria ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Autoimmune connective tissue disorders; Neutralizing autoantibody; Progranulin; Rheumatoid arthritis; Systemic vasculitis; TNF R1 2

Indexed keywords

AUTOANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; PROGRANULIN; PROGRANULIN ANTIBODY; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIINFLAMMATORY ACTIVITY; AORTA ARCH SYNDROME; ARTERITIS; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DNA LIBRARY; HUMAN; MAJOR CLINICAL STUDY; MICROSCOPIC POLYANGIITIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN ARRAY ANALYSIS; SYSTEMIC VASCULITIS;

EID: 84877143211     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.10.003     Document Type: Article

References (44)

1. Davies D.J., Moran J.E., Niall J.F., Ryan G.B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. Br Med J Clin Res Ed 1982, 285:606.
2. Holle J.U., Laudien M., Gross W.L. Clinical manifestations and treatment of Wegener's granulomatosis. Rheum Dis Clin North Am 2010, 36:507-526.
3. Hattar K., Oppermann S., Ankele C., et al. c-ANCA-induced neutrophil-mediated lung injury: a model of acute Wegener's granulomatosis. Eur Respir J 2010, 36:187-195.
4. Jennette J.C., Xiao H., Falk R., Gasim A.M. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol 2011, 169:211-220.
5. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
6. Kain R., Exner M., Brandes R., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008, 14:1088-1096.
7. Kain R., Tadema H., Mckinney E.F., et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012, 23:556-566.
8. Roth A.J., Brown M.C., Smith R.N., et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012, 23:545-555.
9. Navarro M., Cervera R., Font J., et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997, 6:521-526.
10. Schmits R., Kubuschok B., Schuster S., Preuss K.D., Pfreundschuh M. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002, 127:379-385.
11. Ly K.H., Regent A., Tamby M.C., Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition?. Autoimmun Rev 2010, 9:635-645.
12. Regent A., Dib H., Ly K.H., et al. Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Res Ther 2011, 13:R107.
13. Baerlecken N.T., Linnemann A., Gross W.L., et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012.
14. Hoyer B.F., Mumtaz I.M., Loddenkemper K., et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012, 71:75-79.
15. Chanseaud Y., Tamby M.C., Guilpain P., et al. Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg-Strauss syndrome and Wegener's granulomatosis. J Autoimmun 2005, 24:169-179.
16. Guilpain P., Servettaz A., Tamby M.C., et al. A combined SDS-PAGE and proteomics approach to identify target autoantigens in healthy individuals and patients with autoimmune diseases. Ann N Y Acad Sci 2007, 1109:538-549.
17. Dodeller F., Gottar M., Huesken D., Iourgenko V., Cenni B. The lysosomal transmembrane protein 9B regulates the activity of inflammatory signaling pathways. J Biol Chem 2008, 283:21487-21494.
18. Thurner L., Muller A., Cerutti M., et al. Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J Autoimmun 2011, 36:87-90.
19. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
20. Preuss K.D., Pfreundschuh M., Ahlgrimm M., et al. A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer 2009, 125:656-661.
21. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114-119.
22. Toh H., Chitramuthu B.P., Bennett H.P., Bateman A. Structure, function, and mechanism of progranulin; the brain and beyond. J Mol Neurosci 2011, 45:538-548.
23. Bateman A., Bennett H.P. The granulin gene family: from cancer to dementia. Bioessays 2009, 31:1245-1254.
24. Ryan C.L., Baranowski D.C., Chitramuthu B.P., et al. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci 2009, 10:130.
25. Baker M., Mackenzie I.R., Pickering-Brown S.M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919.
26. Sleegers K., Brouwers N., Maurer-Stroh S., et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 2008, 71:253-259.
27. Ong C.H., Bateman A. Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol Histopathol 2003, 18:1275-1288.
28. Cheung P.F., Cheng C.K., Wong N.C., et al. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PLoS One 2011, 6:e28246.
29. Frampton G., Invernizzi P., Bernuzzi F., et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012, 61:268-277.
30. Ho J.C., Ip Y.C., Cheung S.T., et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008, 47:1524-1532.
31. Tang W., Lu Y., Tian Q.Y., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011, 332:478-484.
32. Lai Y., Yu X.P., Zhang Y., et al. Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA. Osteoarthr Cartil 2012, 20:854-862.
33. Bhatia A., Ell P.J., Edwards J.C. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005, 64:1099-1100.
34. Liu C.J. Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett 2011, 585:3675-3680.
35. Sfikakis P.P., Tsokos G.C. Towards the next generation of anti-TNF drugs. Clin Immunol 2011, 141:231-235.
36. Capell A., Liebscher S., Fellerer K., et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 2011, 31:1885-1894.
37. Ghidoni R., Stoppani E., Rossi G., et al. Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter italian study. Neurodegener Dis 2012, 9:121-127.
38. Sleegers K., Brouwers N., Van D.P., et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 2009, 65:603-609.
39. Finch N., Baker M., Crook R., et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009, 132:583-591.
40. Kessenbrock K., Frohlich L., Sixt M., et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest 2008, 118:2438-2447.
41. Zhu J., Nathan C., Jin W., et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111:867-878.
42. Savige J.A., Chang L., Cook L., Burdon J., Daskalakis M., Doery J. Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis. Clin Exp Immunol 1995, 100:194-197.
43. Lyons P.A., Rayner T.F., Trivedi S., et al. Genetically distinct subsets within ANCA-Associated Vasculitis. N Engl J Med 2012, 367:214-223.
44. Maciejewska-Rodrigues H., Al-Shamisi M., Hemmatazad H., et al. Functional autoantibodies against serpin E2 in rheumatoid arthritis. Arthritis Rheum 2010, 62:93-104.